Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 3/20 | 0.81 |
| ▸ | USP30 | Q70CQ3 | 16/20 | 0.72 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17632151 | 1.00 | UCHL1 (0.81) | UCHL1USP30MKNK1 | |
| SCHEMBL17632493 | 0.90 | UCHL1 (0.81) | UCHL1USP30MKNK1 | |
| SCHEMBL17632038 | 0.90 | UCHL1 (1.00) | UCHL1USP30MKNK1 | |
| SCHEMBL17632033 | 0.90 | UCHL1 (1.00) | UCHL1USP30MKNK1 | |
| SCHEMBL17632501 | 0.89 | UCHL1 (0.83) | UCHL1USP30MKNK1 | |
| SCHEMBL29992744 | 0.89 | UCHL1 (0.83) | UCHL1USP30MKNK1 | |
| SCHEMBL30513276 | 0.89 | UCHL1 (0.81) | UCHL1USP30MKNK1 | |
| SCHEMBL17632444 | 0.89 | UCHL1 (0.81) | UCHL1USP30MKNK1 | |
| SCHEMBL17632267 | 0.89 | UCHL1 (0.81) | UCHL1USP30MKNK1 | |
| SCHEMBL17632441 | 0.89 | UCHL1 (0.81) | UCHL1USP30MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | UCHL1 1/4885USP30 20/4885MKNK1 2009/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | UCHL1 1/4885USP30 20/4885MKNK1 2009/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | UCHL1 1/4885USP30 19/4885MKNK1 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.